Pharma Mar, S.A. (FRA:PMRA)

Market Cap	1.53B -3.2%
Revenue (ttm)	221.39M +26.6%
Net Income	74.99M +187.0%
EPS	4.30 +188.7%
Shares Out	n/a
PE Ratio	20.45
Forward PE	22.23
Dividend	0.80 (0.91%)
Ex-Dividend Date	Jun 25, 2025

Volume	60
Average Volume	14
Open	89.85
Previous Close	90.60
Day's Range	88.30 - 89.85
52-Week Range	70.60 - 94.65
Beta	n/a
RSI	59.16
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 505
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PMRA

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.